Research Article
Isolated IgA Anti-β2 Glycoprotein I Antibodies in Patients with Clinical Criteria for Antiphospholipid Syndrome
Table 5
APS morbidity and aPL autoantibodies.
| | Antibodies | Venous thrombosis | Arterial thrombosis | Pregnancy morbidity | | OR | | | OR | | | OR | |
| | aB2GPI IgG |
12 (10%) | 16.9 | <0.0001 | 0 (0%) | 0 | 0.1332 | 2 (8%) | 12.6 | 0.0262 | | aB2GPI IgM | 7 (6%) | 6.2 | 0.0087 | 0 (0%) | 0 | 0.2677 | 1 (4%) | 4 | 0.7265 | | aB2GPI IgA | 36 (30%) | 25.8 | <0.0001 | 7 (54%) | 70.2 | <0.0001 | 3 (12%) | 7.8 | 0.0125 | | aCL IgG | 15 (13%) | 14.4 | <0.0001 | 0 (0%) | 0 | 0.2677 | 2 (4%) | 8.4 | 0.0630 | | aCL IgM | 7 (6%) | 9.4 | 0.0029 | 0 (0%) | 0 | 0.1332 | 1 (8%) | 6 | 0.5671 | | aCL IgA | 7 (6%) | 6.2 | 0.0087 | 1 (0%) | 0 | 0.2677 | 1 (4%) | 4 | 0.7265 | | aB2GP1 IgA (isolated) | 28 (23%) | 18.3 | <0.0001 | 6 (46%) | 51.6 | <0.0001 | 2 (8%) | 5 | 0.1759 | | aCL or aB2GPI (IgG or IgM) | 20 (17%) | 10 | <0.0001 | 0 (0%) | 0 | 0.4994 | 2 (8%) | 4.1 | 0.2445 | | aCL or aB2GPI any isotype | 50 (42%) | 16.1 | <0.0001 | 7 (54%) | 26.2 | <0.0001 | 5 (19%) | 5.3 | 0.0053 |
|
|
